DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PHERGAIN
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
BREAST
(Journal) The Journal of Nuclear Medicine
2024
PHERGain
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial
BREAST
(Journal) Breast Cancer Research and Treatment
2024
PHERGAIN
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
BREAST
(Journal) The Lancet
2024
PHERGAIN
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
BREAST
(Journal) European Journal of Nuclear Medicine and Molecular Imaging
2024
METALLICA
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
BREAST
eClinical Medicine
2024
DEBBRAH
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
BREAST
(Journal) Neuro-Oncology
2023
I3LUNG
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
LUNG
(Journal) Clinical Lung Cancer
2023
PHERGAIN
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)
BREAST
ASCO
2023
DEBBRAH
Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced
Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis:
Results from Cohort 5 of the DEBBRAH Study
BREAST
SABCS
2023
LUPER
Lurbinectedin In Combination With Pembrolizumab In Relapsed Small Cell Lung Cancer (SCLC): The Phase 1/2 LUPER Study
LUNG
ESMO
2023
ORPHEUS
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS
PENIS
ASCO
2023
PHERGAIN (sub-study)
Validation of a genomic assay in early-stage HER2+ breast cancer treated with trastuzumab and pertuzumab (HP): a correlative analysis from PHERGain phase II trial
BREAST
ESMO
2023
Other MEDSIR related articles
